Docetaxel Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy in Triple Negative Breast Cancer
Status: SUSPENDED
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer|Anthracycline-refractory TNBC
Interventions: DRUG: Docetaxel|DRUG: Pembrolizumab|DRUG: IL-12 gene therapy
Sponsor: The Methodist Hospital Research Institute
Collaborators: Merck Sharp & Dohme LLC